Evaluating the Effect of a New Medication for Atopic Dermatitis
The purpose of the study is to evaluate if a new investigational medication, Tralokinumab, works for patients with atopic dermatitis (AD). Earlier studies of Tralokinumab have shown that the medication is effective in patients with AD. This study compares the effects of Tralokinumab to a placebo (no active medicine). To evaluate how well Tralokinumab works, we will perform a range of assessments to see how the severity of AD can decrease and quality of life could be improved.
Effect of Cold Stored Platelets to Slow or Stop Severe Internal Bleeding in Trauma Patients
<p style="text-align: center;"><span style="font-size: 18px;"><strong>Under the FDA rule Exception From Informed Consent (EFIC), severely injured patients taken to LAC+USC Medical Center with internal bleeding <u style="">may be enrolled into this clinical trial without their prior consent</u>. </strong><span style="font-size: 18px;"> </span></span></p><p style="text-align: left;">This site is to inform the public about this upcoming study and to give the public an opportunity to voice their opinion and/or to opt-out of the study in advance.</p><p style="text-align: left;"> </p><p style="text-align: center;">************</p><p style="text-align: left;">Trauma is the leading cause of death in people younger than 45 years. Unfortunately, 40-50% of severely injured patients with internal bleeding die, even after reaching the hospital. This clinical study is about whether Cold Stored Platelets can help slow or stop severe internal bleeding while the patient is being treated by the trauma team. </p><p style="text-align: left;">Platelet transfusions are a vital component of damage control resuscitation and are essential to blood clot formation and early stopping of severe bleeding. In usual care, platelets are stored in room temperature because they survive longer once infused into the body compared to cold-stored platelets. However, there are studies that suggest that cold-stored platelets can still be effective in early stopping of severe bleeding. This study is being done to see if giving Cold-Stored Platelets early in the course of treatment is feasible and if it would help improve outcomes in injured patients that lose a lot of blood.</p><p style="text-align: center;"><br></p><p style="text-align: center;">Scroll down to learn more.</p><p style="text-align: center;"> <br></p>
CD Flex: An Open-Label, Non-Inferiority Study Evaluating the Efficacy and Safety of Two Injection Schedules of Xeomin (incobotulinumtoxinA) [Short Flex vs. Long Flex] in Subjects with Cervical Dystonia with < 10 Weeks of Benefit from OnabotulinumtoxinA Treatment MUS 60201 4073 1
Dystonia is a movement disorder characterized by sustained, involuntary muscle contractions which frequently causes twisting and repetitive movements or abnormal postures. Cervical dystonia (CD) is the most commonly described form of focal dystonia (abnormality involving a single area of the body). Xeomin (botulinum toxin type A), the study drug, has been shown to be effective and safe in the treatment of CD with two Phase III trials. Current practice in the treatment of CD with onabotulinumtoxinA (Botox) injection is to inject patients every 3 months. However, not all patients receive benefit from injections for the duration of 3 months. This study is designed to examine a shorter treatment interval with Xeomin injections and compare to the standard interval to determine if there is a difference from an efficacy standpoint (i.e., do the patients receive continuous benefit versus peaks and valleys) and if more frequent dosing leads to more development of botulinum toxin resistance. This study will evaluate if shorter dosing intervals is non-inferior to standard or longer dosing intervals by using the Toronto Western Spasmodic Torticollis Scale (TWSTRS) at control Visit 4 weeks post the the 8th injection. Secondary outcomes will evaluate efficacy, onset and offste of efficacy, safety and immunology. The primary efficacy variable will be defined as the change from study entry baseline in the TWSTRS-Severity score assessed at the 4-week control visti after the 8th injection (PPS sample). An analysis of covariance (ANCOVA) will be used for the primary efficacy analysis. All analysis of secondary endpoints for efficacy will be considered exploratory.
Help stroke survivors! Join research study on motion, balance and walking
<p> 85% of survivors of stroke experience walking issues, which limit their activities and participation. These issues include decreased coordination and slower walking, which might make people more prone to falls.</p><p> The objective of this study is to measure walking in people shortly after stroke and to identify which aspects of walking early after stroke indicate how well a patient recovers. Identifying these features will help physical therapists customize therapies to promote recovery of walking and help with other balance issues after a stroke. Therefore, we plan to test stroke survivors between 1-6 months after stroke and up to a year after they have suffered a stroke. </p>
All of Us Research Program
<p>The All of Us Research Program is a historic effort to gather information from one million or more people living in the United States. All of Us is a research program funded by the National Institutes of Health (NIH). The mission of the All of Us Research Program is to accelerate health research and medical breakthroughs, enabling individualized prevention, treatment, and care for all of us.</p><p><br></p>
Powered by
SC CTSI